Terence Flynn

Eli Lilly & Co. (NYSE:LLY) has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock’s run-up and its future trajectory. What Happened: Lilly stock...

Shares of Eli Lilly And Co (NYSE: LLY) Tuesday spiked, after the company reported strong second-quarter results. The results came amid an exciting earnings season. Here are some key analyst takeaways from the earnings release. Cantor Fitzgerald On Eli Lilly Analyst Louise Chen maintained an...

Merck & Co., Inc’s (NYSE: MRK) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, according to Goldman Sachs. The Merck Analyst: Terence Flynn upgraded Merck from Neutral to Buy and raised the price...

Gilead Sciences, Inc. (NASDAQ: GILD) shares have come under pressure due to some pipeline misses and an aging product portfolio. The Analyst Goldman Sachs analyst Terrence Flynn downgraded Gilead from Neutral to Sell and lowered the price target from $70 to $60.  The Thesis Gilead's...

Alkermes Plc (NASDAQ: ALKS) has enjoyed a relatively strong Street backing over the last six months despite its nearly 40-percent drop. On Wednesday, though, it caught a downgrade, bringing its ratings mix to six Buys, five Holds and two Sells, according to TipRanks. The Rating Goldman Sachs...

The FDA recently approved Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s patisiran for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The genetic, often lethal, disease leads to abnormal buildup of amyloid protein in peripheral nerves, heart and other...

Acceleron Pharma Inc (NASDAQ: XLRN), a clinical-stage biopharmaceutical focused on the treatment of serious and rare diseases, saw its stock soar after reporting encouraging Phase 3 data. But investors who are aggressive on the stock may want to reconsider, according to Goldman Sachs. The Analyst...

Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...

Goldman Sachs stuck to its Buy rating on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), which delayed filing of its third-quarter report as it is under investigation regarding its sales practices of lead drug Soliris based on the allegations of a former employee. The Investigation Soliris is...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the discontinuation of the development of its late stage pipeline drug, Revusiran due to safety concerns. Goldman Sachs’ Terence Flynn maintained a Neutral rating on the company, while lowering the price target from $65 to $34....

Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...

Despite the recent weakening of the GBP and EUR against the USD, there is limited impact to the 2Q-4Q 2016 figures, and most biotech companies under coverage exhibit a negative effect of less than 1 percent, Goldman Sachs’ Terence Flynn said in a report. The NBI is down 26 percent, versus...

Following in the delay in the release of data by Amgen, Inc. (NASDAQ: AMGN) for its ongoing Repatha Phase 3 trials, Goldman Sachs’ Terence Flynn now believes that the Phase 3 IVUS data could be a more important near-term catalyst for the stock. Flynn maintains a Buy rating on the company,...